There are some reductions. There may be about 3% reduction, is the number that comes to mind, in areas that were of lower priority research, but all of the research areas, the scientific areas involved in compliance and enforcement, all of the drug reviews the minister spoke of, the pre-market and post-market, all of those areas have been retained or strengthened.
On November 20th, 2012. See this statement in context.